Trisha Wise-Draper, MD, PhD

Wise-Draper briefly explains the study that Nooshin Hashemi Sadraei, MD, conducted on patients with HNC, as well as the importance of looking at QOL. Sadraei used certified QOL surveys with patients undergoing chemotherapy and radiation. Results from the survey showed correlations with the ending adverse effects.

In future studies, Wise-Draper states that Sadraei plans to use immunotherapies in hopes of reducing the adverse effects and improving QOL.

Trisha Wise-Draper, MD, PhD, assistant professor, University of Cincinnati, discusses the quality of life (QOL) as a predictor of clinical outcome in patients with head and neck cancer (HNC).

Trisha Wise-Draper, MD, PhD | Authors

Articles

Quality of Life as a Predictor of Clinical Outcome in Patients With HNC